Effectiveness and safety OF Brimonidine tartrate in treatment of glaucoma
Phase 2
- Conditions
- Health Condition 1: null- diagnosed with OHTor OAG in one or both eyesHealth Condition 2: H401- Open-angle glaucoma
- Registration Number
- CTRI/2015/12/006473
- Lead Sponsor
- Sun Pharma Advanced Research Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Willing and able to give written informed consent.
-diagnosis of OHG or OAG
-Unmedicated IOP >= 22 mmHg and <= 36 mm Hg in one or
both eyes
-Women of child bearing potential practicing an acceptable method of birth control
Exclusion Criteria
-Women who are Pregnant nursing or planning a pregnancy or who were of childbearing potential and not using reliable method of contraception
-Known lack of ocular hypotensive response to topical ophthalmic alpha adrenergic receptor agonists in the opinion of the Investigator
-Severe or serious hypersensitivity to alpha-adrenergic agonist drugs
-Intraocular conventional surgery in any eye within the past six months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method